Introduction The KEYNOTE-689 clinical trial has provided a significant update on pembrolizumab’s role in treating resectable locally advanced head and…
Browsing: KEYTRUDA
Date: March 19, 2025 On March 19, 2025, the U.S. Food and Drug Administration (FDA) granted traditional approval to pembrolizumab…
The FDA has approved pembrolizumab (Keytruda) combined with platinum-based chemotherapy for the treatment of patients with unresectable, advanced, or metastatic…
Corina Dutcus, MD from Eisai Inc provided a summary of the findings from a clinical trial evaluating the combination of…